Application progress of recombinant human endostatin in the treatment of head and neck cancer

doi:10.12016/j.issn.2096-1456.2020.04.012

Abstract

Abstract:

The main treatment of head and neck cancer is comprehensive sequential treatment, but the 5-year overall survival rate is less than 50%. Strategies to further improve the curative effect of head and neck cancer are urgently needed in the clinic. Recombinant human vascular endostatin is an antiangiogenesis drug targeting vascular endothelial cells, which has a certain inhibitory effect on tumors. The treatment of malignant tumors by drugs alone is not significantly better than chemoradiation, but combined with radiotherapy and chemotherapy, it can increase the effect of radiotherapy and chemotherapy without drug resistance by changing the distribution of blood vessels, reducing oxygen and normalizing blood vessels. Head and neck tumor treatment has certain advantages. New tumor treatments are expected. The results of a literature review showed that the mechanism of action of recombinant human endostatin mainly includes regulating the matrix protein inside and outside the endothelial cells to influence neovascularization, acting on receptors related to the surface of endothelial cells, reversing abnormal neovascularization to achieve vascular normalization, inhibiting hypoxia inducible factor to improve the hypoxic status of the tumor area, and regulating the cell cycle to ensure the tumor cells are sensitive to radiation in the sensitive period, and vascular normalization can increase the effect of radiotherapy. This treatment has a good synergistic effect with radiotherapy and chemotherapy of head and neck tumors and has a good effect on advanced head and neck tumors.

Key words: recombinant human endostatin, head and neck cancer, vascular normalization, vascular endothelium, targeted drug, targeted therapy, biotherapy, chemotherapy synergy, radiosensitive phase

摘要：

头颈部恶性肿瘤的治疗方式主要是以手术切除为主的综合序列治疗,但5年总生存率提高不足50%,如何进一步提高头颈部恶性肿瘤治疗成功率成为临床中亟待解决的问题。重组人血管内皮抑素是一种靶点为血管内皮细胞的抗血管生成靶向药物,具有一定的抑制肿瘤的作用。单独用药治疗恶性肿瘤并不明显优于放化疗,但联合放化疗,可以通过改变肿瘤内部血管分布,改善肿瘤内部缺氧,促使血管正常化增加放化疗效果,且不产生药物抵抗,在头颈部恶性肿瘤治疗中表现出一定的优势,有望成为一种新的肿瘤治疗方法。文献复习结果表明,重组人血管内皮抑素作用机制主要包括调节内皮细胞内外基质蛋白影响新生血管生成;作用于内皮细胞表面相关受体;逆转异常新生血管达到血管正常化;抑制低氧诱导因子,改善肿瘤区域缺氧状态;调控细胞周期,使更多的肿瘤细胞处于放射敏感期以及使血管正常化窗口增加放化疗效果。其在头颈部恶性肿瘤放化疗协同作用以及在晚期头颈部恶性肿瘤中应用效果良好,为临床医生提供一种继放化疗之后又一抗肿瘤方法。

关键词: 重组人血管内皮抑素, 头颈部恶性肿瘤, 血管正常化, 血管内皮, 靶向药物, 靶向治疗, 生物治疗, 化疗协同作用, 放射敏感期

CLC Number:

R78
R739.8

LI Xiaodong,MENG Jian. Application progress of recombinant human endostatin in the treatment of head and neck cancer[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(4): 267-272.

李晓东,孟箭. 重组人血管内皮抑素在治疗头颈部恶性肿瘤中的应用进展[J]. 口腔疾病防治, 2020, 28(4): 267-272.

References 39

[1]	O′Reilly MS, Boehm T, Shing Y , et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997,88(2):277-285.
[2]	Mohajeri A, Sanaei S, Kiafar F , et al. The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering[J]. Adv Pharm Bull, 2017,7(1):21-34.
[3]	Zhou S, Zuo L, He X , et al. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: a retrospective comparison with standard chemotherapy[J]. Thorac Cancer, 2018,9(11):1354-1360.
[4]	Qin RS, Zhang ZH, Zhu NP , et al. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma[J]. BMC Cancer, 2018,18(1):967.
[5]	刘书昊, 潘运龙, 覃莉 , 等. 纳米金结合重组人血管内皮抑素对人脐静脉内皮细胞增殖、凋亡及迁移的影响[J]. 中华实验外科杂志, 2018,35(4):645-648.
	Liu SH, Pan YL, Qin L , et al. The effect of the gold nanoparticles combined with endostar on proliferation, apoptosis, migration of human umbilical vein endothelial cells[J]. Chin J Exp Surg, 2018,35(4):645-648.
[6]	Nemoto T, Kubota S . Vascular endothelial cadherin is an endostatin receptor[J]. Biologia (Bratislava), 2011,66(4):721-726.
[7]	Xu X, Mao W, Chen Q , et al. Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway[J]. PLoS One, 2014,9(9):e107463.
[8]	Zhang Q, Cao J, Xue K , et al. Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma[J]. Onco Targets Ther, 2016,10:145-151.
[9]	Xiao L, Yang S, Hao J , et al. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis[J]. Cancer Lett, 2015,359(1):148-154.
[10]	Ning T, Jiang M, Peng Q , et al. Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model[J]. Thorac Cancer, 2012,3(3):229-238.
[11]	Fu W, Zhuo J, Hu L . Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer[J]. Oncol Lett, 2017,13(1):196-200.
[12]	Yu M, Han Y, Zhuo H , et al. Endostar, a modified endostatin induces vascular normalization to improve chemotherapy efficacy through suppression of src signaling pathway[J]. Cancer Biother Radiopharm, 2018,33(4):131-138.
[13]	Li W, Zhao X, Du B , et al. Gold nanoparticle-mediated targeted delivery of recombinant human endostatin normalizes tumour vasculature and improves cancer therapy[J]. Sci Rep, 2016,6:30619.
[14]	Jin T, Li B, Chen XZ . A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286)[J]. Oncol Res, 2013,21(6):317-323.
[15]	Jin T, Jiang F, Jin QF , et al. Endostar combined with gemcitabine and cisplatin chemotherapy for patients with metastatic nasopharyngeal carcinoma: an update[J]. Transl Oncol, 2018,11(2):286-291.
[16]	Chen J, Yao Q, Huang M , et al. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01)[J]. Int J Cancer, 2018,142(10):2130-2138.
[17]	Chen C, Liu SR, Zhou S , et al. Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: three case reports[J]. Medicine (Baltimore). 2019,98(32):e16592.
[18]	Lu S, Li L, Luo Y , et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer[J]. J Thorac Oncol, 2015,10(1):206-211.
[19]	Chen J, Qi J, Yu B , et al. A retrospective study to compare five induction chemotherapy regimens prior to radiotherapy in the reduction of regional lymph node size in patients with nasopharyngeal carcinoma[J]. Med Sci Monit, 2018,24:2562-2568.
[20]	Zhang K, Wang Y, Yu X , et al. Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth[J]. BMC Cancer, 2017,17(1):899.
[21]	Liu GF, Chang H, Li BT , et al. Effect of recombinant human endostatin onradiotherapy for esophagus cancer[J]. Asian Pac J Trop Med, 2016,9(1):86-90.
[22]	Zheng YF, Ge W, Xu HL , et al. Endostar enhances the antitumor effects of radiation by affecting energy metabolism and alleviating the tumor microenvironment in a Lewis lung carcinoma mouse model[J]. Oncol Lett, 2015,10(5):3067-3072.
[23]	Zhang L, Ge W, Hu K , et al. Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells[J]. Mol Biol Rep, 2012,39(1):89-95.
[24]	He L, Zhao C, Li Y , et al. Antiangiogenic effects of recombinant human endostatin in lung cancers[J]. Mol Med Rep, 2018,17(1):79-86.
[25]	何朗, 刘康, 陈梅 , 等. 重组人血管内皮抑素联合顺铂不同时相治疗小鼠Lewis肺癌移植瘤疗效观察[J]. 中华肿瘤防治杂志, 2018,25(20):1422-1428.
	He L, Liu K, Chen M , et al. Effect of recombinant human endostatin combined with cisplatin on different stages of Lewis lung cancer xenograft in mice[J]. Chin J Cancer Prev Treat, 2018,25(20):1422-1428.
[26]	Chen X, Zhang H, Zhu H , et al. Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer[J]. Tumour Biol, 2016,37(4):4679-4688.
[27]	Zhu H, Yang X, Ding Y , et al. Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia[J]. Sci Rep, 2015,5:14503.
[28]	Kareemaghay S, Tavassoli M . Clinical immunotherapeutic approaches for the treatment of head and neck cancer[J]. Int J Oral Maxillofac Surg, 2019,48(4):419-436.
[29]	Ye W, Liu R, Pan C , et al. Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma[J]. Mol Ther, 2014,22(6):1221-1229.
[30]	Kang M, Wang F, Liao X , et al. Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma[J]. Medicine (Baltimore), 2018,97(25):e11118.
[31]	Mardani M, Andishe TA, Ranjbar MA , et al. Serum endostatin levels in oral squamous cell carcinoma[J]. Iran J Otorhinolaryngol, 2018,30(98):125-130.
[32]	Alahuhta I, Aikio M, Vayrynen O , et al. Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment[J]. Exp Cell Res, 2015,336(1):130-140.
[33]	Li Y, Jin F, Wu W , et al. Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma[J]. Zhonghua Zhong Liu Za Zhi, 2015,37(2):128-132.
[34]	Cheng Y, Nie L, Liu Y , et al. Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer[J]. Thorac Cancer, 2019,10(7):1576-1580.
[35]	Folkman J . Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action[J]. Exp Cell Res, 2006,312(5):594-607.
[36]	Chen Z, Luo Q, Zhou Z , et al. Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression[J]. Oncotarget, 2017,8(45):79703-79711.
[37]	Yan M, Dongmei B, Jingjing Z , et al. Antitumor activities of liver-targeting peptide modified recombinant human endostatin in BALB/c-nu mice with hepatocellular carcinoma[J]. Sci Rep, 2017,7(1):14074.
[38]	Xing S, Fan Z, Shi L , et al. Successful treatment of brain radiation necrosis resulting from triple-negative breast cancer with Endostar and short-term hyperbaric oxygen therapy: a case report[J]. Onco Targets Ther, 2019,12:2729-2735.
[39]	Li BL, Hu XL, Zhao XH , et al. Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: a clinical study[J]. J Chemother, 2015,27(5):301-306.